The University of British Columbia
UBC - A Place of Mind
The University of British Columbia
Faculty of MedicineThis Changed My Practice (TCMP) by UBC CPD
  • ⌂ Articles
  • Authors
  • Submit an Article
  • Subscribe
  • Key Features | 0.25 cr/article
  • About
  • UBC CPD ↗

» This Changed My Practice » Diabetes

Diabetes

Support

Lifestyle interventions in type 2 diabetes

By Dr. Sarah McCorquodale on June 17, 2024

Having evidence that remission of type 2 diabetes is possible through weight loss in select people, I have changed my approach to prevention and management of type 2 diabetes.

HDC Discover Dashboard

Using data for practice quality improvement to address blood sugar challenges for complex care patient

By Dr. Omesh Syal on April 15, 2024

I highly recommend registering with the Health Data Coalition and becoming more familiar with your measures within the HDC Discover application to recognize your contribution. We, as a collective profession, can make a positive impact on our own practices and larger communities.

SGLT2i in patients with diabetes: translating an evolving body of evidence to the nuances of practice

SGLT2i in patients with diabetes: translating an evolving body of evidence to the nuances of practice

By Jamison Falk, PharmD on June 19, 2023

While I’ve been hard on newer medications like SGLT2i for their relatively small benefit in lower-risk patients, recent systematic reviews show that our traditional interventions are no better, and may be worse, at reducing risks of outcomes. I now discuss the option of adding an SGLT2i with patients with diabetes and pre-existing cardiovascular or renal disease or with symptomatic hyperglycemia where blood glucose reduction would be expected to reduce day-to-day symptoms. I reduce or discontinue doses of other antihyperglycemic medications if possible when starting an SGLT2i and I educate patients about potential adverse events.

Advances in diabetes glucose monitoring

Advances in diabetes glucose monitoring

By Gerri Klein on January 12, 2022

For all my patients who are on hypoglycemic medications, oral or injectable, I suggest using rtCGM or isCGM. Even intermittent use or a short trial of 10 days to two weeks with either of these devices can be enlightening for patients. With the ongoing COVID restrictions, many of my patients have been unable (or unwilling) to obtain an A1C from a lab test. In my practice, I have found it helpful to use glucose TIR to assess glucose control as an adjunct measure to A1C results; when an A1C is not available; and to guide treatment recommendations.

Heart

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: New drug class in the treatment of Heart Failure with Reduced Ejection Fraction — DAPA-HF and EMPEROR-Reduced trials

By Tanveer Brar BSc BSc(Pharm) ACPR, Doson Chua BSc(Pharm) PharmD FCSHP BCPS BCCP, and Laura Atiyeh on January 13, 2021

Heart failure (HF) is a clinical syndrome associated with significant morbidity and mortality. In 2020, the prevalence of HF was approximately 64.34 million cases (8.52 per 1,000 inhabitants) worldwide and this number has been steadily increasing over time. There is compelling evidence to suggest that in individuals with HFrEF in the presence or absence of T2DM, both dapagliflozin and empagliflozin have profound effects on reduction of HF hospitalizations and possibly CV mortality.

Plant based diet

Recommending a plant-based diet

By Dr. Jan Hajek on August 3, 2016

For diabetes in particular, observational studies suggest that persons who follow a plant-based diet have a lower risk for diabetes, and an RCT demonstrated reductions in HbA1c in patients with diabetes randomized to a vegan diet compared to the standard American Diabetes Association diet.

Heart

Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction: The TOPCAT and ALDO-DHF trials

By Dr. Mustafa Toma and Dr. Christopher Cheung on May 27, 2015

There are approximately 500,000 Canadians living with heart failure, and more than 10% in patients older than 65. Up to 50% of patients presenting with signs and symptoms of heart failure will have a preserved ejection fraction (HFpEF or diastolic dysfunction). However, there is a lack of evidence for effective therapies in the management of HFpEF.

Tailoring therapy for type 2 diabetes: the role of incretins

Incretin Safety: What is the Evidence?

By Dr. Breay Paty on February 18, 2015

Nausea can be a common side effect of GLP-1 receptor agonist, which can sometimes be dose limiting. However, this usually improves with time. As a new class of agents, evidence for the long-term safety of incretins is still emerging. Most of the safety questions involve cardiovascular (CV) risk, as well as pancreatitis and pancreatic cancer.

Diabetes and exercise

Diabetes and exercise

By Dr. Andrew Farquhar on May 14, 2012

I direct more effort to encouraging physical activity as a critical tool in the management of T2D. I emphasize a healthy diet but stress that weight loss is not the primary goal, exercise is.

female-patient

Tailoring therapy for type 2 diabetes: the role of incretins

By Dr. Breay Paty on January 23, 2012

These oral agents, administered once daily, augment endogenous GLP-1, resulting in an A1C reduction of 0.5 – 0.9%. Since GLP-1 does not directly stimulate insulin, they have the advantage of not promoting hypoglycemia or weight gain.

This app changed my practice: Pocket A1C

This app changed my practice: Pocket A1C

By Dr. Steve Wong on July 20, 2011

In response to reader requests and the increasing interest in mobile apps, we are launching a series of articles highlighting useful iPhone apps. These will appear approximately once every three months.

Tailoring therapy for type 2 diabetes: the role of incretins

New targets for Diabetes (A1C): Why we are aiming at ‘only’ 7 percent

By Dr. Breay Paty on June 20, 2011

Recent studies suggest that the relationship between glucose control (A1C) and cardiovascular disease is more complex than we may have realized.

New study on the use of erythropoietin stimulating agents in chronic kidney disease has made us evaluate the risk-benefit of ESA’s in CKD patients not on dialysis.

By Dr. Monica Beaulieu on June 14, 2010

The evidence strongly suggests that there is little to no benefit gained by raising the Hb over > 100g/L (and perhaps even lower) in diabetic patients with CKD not on dialysis.

Heart

What are the CV risks of TZDs: have the safety questions been answered?

By Dr. Breay Paty on April 15, 2010

Since their introduction, certain contraindications and side effects have been well known, including worsening heart failure, edema (including macular edema) and weight gain.


Recent Articles

  • Diagnosis of anxiety conditions in primary care: Part 1
  • Environmental impacts of clinical practice: reducing unnecessary care
  • Buprenorphine/naloxone for chronic non-cancer pain
  • Menopause: Don’t sweat it: Part 1
  • Trauma-informed high impact chronic pain care
  • Letter from the editor

Recent Comments

  • K on Interpretation of Syphilis Serology
  • Scott Brill on Interpretation of Syphilis Serology
  • Dr. Douglas Green on Diagnosis of anxiety conditions in primary care: Part 1
  • Paul Harris on Diagnosis of anxiety conditions in primary care: Part 1
  • Marjolaine Savoie on Identifying and treating iron deficiency in patients hospitalized for heart failure
  • Maryanne C Roy on Diagnosis of anxiety conditions in primary care: Part 1

Visit UBC CPD at ubccpd.ca

UBC CPD website

View all CPD learning activities: virtual, in-person and hybrid conferences, workshops, webinars, online modules, customized community courses, simulation hands-on courses, coaching, mentoring, personalized learning, recordings, and more.

Visit UBC CPD ↗

  • Medical Area
  • Popular Topics
  • Addiction Medicine
  • Allergy/ Immunology
  • Announcements
  • Cardiology
  • Dermatology
  • Emergency Medicine
  • Endocrinology
  • Family Medicine
  • Gastroenterology
  • Geriatrics
  • Hematology
  • Hepatology
  • Infectious Disease
  • Internal Medicine
  • Nephrology
  • Neurology
  • Obstetrics and Gynaecology
  • Oncology
  • Ophthalmology
  • Orthopaedics
  • Otorhinolaryngology or ENT (ear, nose and throat)
  • Palliative Care
  • Pediatrics
  • Physiatry
  • Physical Medicine and Rehabilitation
  • Practice
  • Psychiatry
  • Public Health
  • Respirology
  • Rheumatology
  • Sport Medicine
  • Surgery
  • Teaching
  • Technology
  • Travel Medicine
  • Uncategorized
  • Urology
  • Wellness
  • Addiction Antibiotics Apps Arthritis Atrial fibrillation Beta blockers Billing Blood work Cardiovascular Children Chronic pain Cognitive behavioural therapy Contraception COVID-19 Depression Diabetes Elderly Estrogen Exercise GI tract Guidelines Heart Heart failure Hepatitis C Infants Infections iOS IUD Kidney disease Liver Mental health Opioids Pain Patient handouts Practice change Practice tip Pregnancy Resources Resources for practitioners Sexual medicine Teaching Thrombosis Vaccine Well-being Women's health
    This field is for validation purposes and should be left unchanged.

    Disclaimer
    This Changed My Practice (TCMP) by UBC CPD | Continuing Professional Development
    Faculty of Medicine
    City Square, 200-555 W 12th Ave
    Vancouver, BC Canada V5Z 3X7
    Tel 604 675 3777
    Fax 604 675 3778
    Website ubccpd.ca
    Email tcmp.cpd@ubc.ca
    Find us on
        
    Back to top
    The University of British Columbia
    • Emergency Procedures |
    • Terms of Use |
    • Copyright |
    • Accessibility